Volume 13, Issue 4 (12-2025)                   JoMMID 2025, 13(4): 240-245 | Back to browse issues page

Ethics code: grant number 2271

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Taheri T. Genetic Diversity, Plasticity, and Gene Manipulation Strategies in Leishmania: Implications for Treatment and Vaccine Research. JoMMID 2025; 13 (4) :240-245
URL: http://jommid.pasteur.ac.ir/article-1-817-en.html
Genetic Diversity, Plasticity, and Gene Manipulation Strategies in Leishmania: Implications for Treatment and Vaccine Research
Tahereh Taheri *
Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (253 Views)
Leishmaniasis is a neglected tropical disease (NTD) that remains a significant global health challenge. While a small number of drugs are clinically effective, their use is constrained by toxicity, high cost, and emerging drug resistance. Furthermore, no licensed human vaccine is currently available. Leishmania exhibits extensive genomic plasticity, primarily through aneuploidy, gene copy number variations (CNVs), and subtelomeric amplifications, which confer remarkable flexibility and rapid adaptation to adverse environments, such as those encountered within the host or during drug treatment. Moreover, the extensive genetic diversity and plasticity of Leishmania enable it to rapidly adjust gene expression in response to environmental changes, facilitating adaptation to various stressors, including host immune responses and drug exposure. This adaptability significantly complicates effective treatment. In addition to vertical gene transfer, genetic exchange through hybridization and karyotypic instability are well-documented mechanisms that enhance the parasite's capacity to adapt to environmental stress. The role of horizontal gene transfer remains under investigation. This mini-review highlights the unique genomic features of Leishmania, particularly its genetic flexibility and unconventional mechanisms of gene expression regulation, such as aneuploidy and CNVs. It also examines major genetic manipulation tools used to investigate parasite biology, while discussing their inherent limitations. Understanding gene function is essential yet remains challenging due to the parasite's atypical genome organization and regulatory mechanisms. A deeper comprehension of Leishmania genetics is therefore crucial for the rational design of effective drugs and vaccines.
Keywords: Leishmaniasis, Leishmania, Genetic diversity, Genomic plasticity, Treatment, Vaccine, Gene manipulation
Full-Text [PDF 801 kb]   (175 Downloads)    
Type of Study: Mini Review | Subject: Microbial pathogenesis
Received: 2026/02/3 | Accepted: 2025/12/10 | Published: 2026/02/3
References
1. Knight CA, Harris DR, Alshammari SO, Gugssa A, Young T, Lee CM. Leishmaniasis: recent epidemiological studies in the Middle East. Front Microbiol. 2023; 13: 1052478. [DOI:10.3389/fmicb.2022.1052478] [PMID] [PMCID]
2. World Health Organization. Global report on neglected tropical diseases 2023. Geneva: World Health Organization; 2023.
3. Klatt S, Simpson L, Maslov DA, Konthur Z. Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host. PLoS Negl Trop Dis. 2019; 13 (7): e0007424. [DOI:10.1371/journal.pntd.0007424] [PMID] [PMCID]
4. Cosma C, Maia C, Khan N, Infantino M, Del Riccio M. Leishmaniasis in humans and animals: a one health approach for surveillance, prevention and control in a changing world. Trop Med Infect Dis. 2024; 9 (11): 258. [DOI:10.3390/tropicalmed9110258] [PMID] [PMCID]
5. de Almeida M, Zheng Y, Nascimento FS, Bishop H, Cama VA, Batra D, et al. Cutaneous leishmaniasis caused by an unknown Leishmania strain, Arizona, USA. Emerg Infect Dis. 2021;27(6):1714-7. [DOI:10.3201/eid2706.204198] [PMID] [PMCID]
6. Sapp SG, Low R, Nine G, Nascimento FS, Qvarnstrom Y, Barratt JL. Genetic characterization and description of Leishmania (Leishmania) ellisi sp. nov.: a new human-infecting species from the USA. Parasitol Res. 2024; 123 (1): 52. [DOI:10.1007/s00436-023-08034-8] [PMID] [PMCID]
7. Zimna M, Krol E. Leishmania tarentolae as a platform for the production of vaccines against viral pathogens. npj Vaccines. 2024; 9 (1): 212. [DOI:10.1038/s41541-024-01005-9] [PMID] [PMCID]
8. Bandi C, Mendoza-Roldan JA, Otranto D, Alvaro A, Louzada-Flores VN, Pajoro M, et al. Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniases and viral infections. Parasit Vectors. 2023; 16 (1): 35. [DOI:10.1186/s13071-023-05651-1] [PMID] [PMCID]
9. Varotto-Boccazzi I, Manenti A, Dapporto F, Gourlay LJ, Bisaglia B, Gabrieli P, et al. Epidemic preparedness-Leishmania tarentolae as an easy-to-handle tool to produce antigens for viral diagnosis: application to COVID-19. Front Microbiol. 2021; 12: 736530. [DOI:10.3389/fmicb.2021.736530] [PMID] [PMCID]
10. LeBowitz JH, Smith HQ, Rusche L, Beverley SM. Coupling of poly (A) site selection and trans-splicing in Leishmania. Genes Dev. 1993; 7 (6): 996-1007. [DOI:10.1101/gad.7.6.996] [PMID]
11. Liang X-h, Haritan A, Uliel S, Michaeli S. Trans and cis splicing in trypanosomatids: mechanism, factors, and regulation. Eukaryot Cell. 2003; 2 (5): 830-40. [DOI:10.1128/EC.2.5.830-840.2003] [PMID] [PMCID]
12. Taheri T, Seyed N, Mizbani A, Rafati S. Leishmania-based expression systems. Appl Microbiol Biotechnol. 2016; 100 (17): 7377-85. [DOI:10.1007/s00253-016-7712-4] [PMID]
13. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine. 2009; 28 (1): 53-62. [DOI:10.1016/j.vaccine.2009.09.114] [PMID]
14. Zhang W-W, Mendez S, Ghosh A, Myler P, Ivens A, Clos J, et al. Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem. 2003; 278 (37): 35508-15. [DOI:10.1074/jbc.M305030200] [PMID]
15. Azizi H, Hassani K, Taslimi Y, Najafabadi HS, Papadopoulou B, Rafati S. Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. Parasitology. 2009; 136 (7): 723-35. [DOI:10.1017/S0031182009005873] [PMID]
16. Iantorno SA, Durrant C, Khan A, Sanders MJ, Beverley SM, Warren WC, et al. Gene expression in Leishmania is regulated predominantly by gene dosage. mBio. 2017; 8 (5): e01393-17. [DOI:10.1128/mBio.01393-17] [PMID] [PMCID]
17. Grünebast J, Clos J. Leishmania: responding to environmental signals and challenges without regulated transcription. Comput Struct Biotechnol J. 2020; 18: 4016-23. [DOI:10.1016/j.csbj.2020.11.058] [PMID] [PMCID]
18. Späth GF, Piel L, Pescher P. Leishmania genomic adaptation: more than just a 36-body problem. Trends Parasitol. 2025; 41 (6): 441-8. [DOI:10.1016/j.pt.2025.04.002] [PMID]
19. Santi AMM, Murta SMF. Impact of genetic diversity and genome plasticity of Leishmania spp. in treatment and the search for novel chemotherapeutic targets. Front Cell Infect Microbiol. 2022; 12: 826287. [DOI:10.3389/fcimb.2022.826287] [PMID] [PMCID]
20. Carrasco M, Martí-Carreras J, Gómez-Ponce M, Alcover MM, Roura X, Ferrer L, et al. Drug-resistance biomarkers in Leishmania infantum through nanopore-based detection of aneuploidy and gene copy number variations with LeishGenApp [Preprint]. bioRxiv. 2025 [posted 2025 Jan 24;cited 2025 Dec 16]. Available from: https://www.biorxiv.org/content/10.1101/2025.01.23.634476v1 doi: 10.1101/2025.01.23.634476. [DOI:10.1101/2025.01.23.634476]
21. Titus RG, Gueiros-Filho FJ, De Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA. 1995; 92 (22): 10267-71. [DOI:10.1073/pnas.92.22.10267] [PMID] [PMCID]
22. Jones NG, Catta-Preta CM, Lima APC, Mottram JC. Genetically validated drug targets in Leishmania: current knowledge and future prospects. ACS Infect Dis. 2018; 4 (4): 467-77. [DOI:10.1021/acsinfecdis.7b00244] [PMID] [PMCID]
23. Beneke T, Madden R, Makin L, Valli J, Sunter J, Gluenz E. A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids. R Soc Open Sci. 2017; 4 (5): 170095. [DOI:10.1098/rsos.170095] [PMID] [PMCID]
24. Zhang W-W, Matlashewski G. CRISPR-Cas9-mediated genome editing in Leishmania donovani. mBio. 2015; 6 (4): e00861-15. [DOI:10.1128/mBio.00861-15] [PMID] [PMCID]
25. Herrmann May N, Cao A, Schmid A, Link F, Arias-del-Angel J, Meiser E, et al. Improved base editing and functional screening in Leishmania via co-expression of the AsCas12a ultra variant, a T7 RNA polymerase, and a cytosine base editor. eLife. 2025; 13: RP97437. [DOI:10.7554/eLife.97437.3] [PMCID]
26. Beneke T, Gluenz E. Gene editing and scalable functional genomic screening in Leishmania species using the CRISPR/Cas9 cytosine base editor toolbox LeishBASEedit. eLife. 2023; 12: e85605. [DOI:10.7554/eLife.85605] [PMID] [PMCID]
27. Zhang W-W, Matlashewski G. Evidence for gene essentiality in Leishmania using CRISPR. PLoS One. 2024; 19 (12): e0316331. [DOI:10.1371/journal.pone.0316331] [PMID] [PMCID]
28. Lye LF, Owens K, Shi H, Murta SM, Vieira AC, Turco SJ, et al. Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog. 2010; 6 (10): e1001161. [DOI:10.1371/journal.ppat.1001161] [PMID] [PMCID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.